Safety and Efficacy Study of Sebelipase Alfa in Participants With Lysosomal Acid Lipase Deficiency

Completed · Phase 2

Conditions studied: Lysosomal Acid Lipase Deficiency

In brief

This study evaluated the safety and efficacy of sebelipase alfa in a broad population of participants with lysosomal acid lipase deficiency (LAL-D).

Key facts

Study ID

NCT02112994

Run by

Alexion Pharmaceuticals, Inc.

People needed

31

Starts

2014-06-24

Expected to finish

2017-12-28

Last updated by the study team

2019-12-04

Who can join

Age: 1 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Study site — Chicago, Illinois, United States
• Study site — Shreveport, Louisiana, United States
• Study site — Cincinnati, Ohio, United States
• Study site — Westmead, Australia
• Study site — Brussels, Belgium
• Study site — São Paulo, Brazil
• Study site — Halifax, Nova Scotia, Canada
• Study site — Zagreb, Croatia
• Study site — Copenhagen, Denmark
• Study site — Freiburg im Breisgau, Germany
• Study site — Padova, Italy
• Study site — Mexico City, Mexico
• Study site — Amsterdam, Netherlands
• Study site — Moscow, Russia
• Study site — A Coruña, Spain
• Study site — Barcelona, Spain
• Study site — Madrid, Spain
• Study site — Balcalı, Turkey (Türkiye)
• Study site — Birmingham, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.